SCHEMBL4423907

SCHEMBL4423907

Fc1cc(NCC2C3CN(Cc4ccncc4)CC23)ccc1N1CCOCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.50
MAPT P10636 4/20 0.42
KDM4E B2RXH2 2/20 0.42
ALOX12 P18054 1/20 0.42
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
USP30 Q70CQ3 1/20 0.39
MAPK1 P28482 1/20 0.39
MTOR P42345 1/20 0.38
TSHR P16473 2/20 0.38
GAA P10253 2/20 0.38
DGAT1 O75907 1/20 0.37
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4413699 0.90 GAA (0.48) HTTMAPTNPC1RAB9AKMT2A
SCHEMBL4419245 0.90 NPC1 (0.46) HTTMAPTKDM4ENPC1RAB9A
SCHEMBL4412370 0.90 L3MBTL1 (0.44) HTTMAPTNPC1RAB9AKMT2A
SCHEMBL4552124 0.89 P2RX3 (0.43) HTTMAPTKDM4ENPC1RAB9A
SCHEMBL4417584 0.89 KDM4E (0.47) HTTMAPTKDM4ENPC1RAB9A
SCHEMBL4414914 0.89 HIF1A (0.47) HTTKDM4ENPC1RAB9AKMT2A
SCHEMBL4419448 0.88 NOS2 (0.42) HTTMAPTL3MBTL1LMNAMTOR
SCHEMBL4419284 0.88 NPC1 (0.43) HTTMAPTNPC1RAB9AKMT2A
SCHEMBL2170676 0.88 LMNA (0.44) HTTMAPTNPC1RAB9AKMT2A
SCHEMBL4412123 0.88 L3MBTL1 (0.41) HTTMAPTNPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 HTT 1090/4885MAPT 1368/4885KDM4E 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.